COLISTIMIXIN PHEBRA colistimethate sodium 1million IU powder for nebuliser solution vial

Nazione: Australia

Lingua: inglese

Fonte: Department of Health (Therapeutic Goods Administration)

Principio attivo:

colistimethate sodium, Quantity: 1 million IU

Commercializzato da:

Phebra Pty Ltd

INN (Nome Internazionale):

Colistimethate sodium

Forma farmaceutica:

Inhalation

Composizione:

Excipient Ingredients:

Via di somministrazione:

Inhalation

Confezione:

30 vial

Tipo di ricetta:

(S4) Prescription Only Medicine

Indicazioni terapeutiche:

Colistimixin Phebra powder for nebuliser solution is indicated for the treatment of colonisation and infections of the lung due to susceptible Pseudomonas aeruginosa in patients with cystic fibrosis. Consideration should be given to official guidance on the appropriate use of antibacterial agents.

Dettagli prodotto:

Visual Identification: White to off-white powder; Container Type: Vial; Container Material: Glass Type I Clear; Container Life Time: 3 Years; Container Temperature: Store below 25 degrees Celsius; Container Closure: Neither child resistant closure nor restricted flow insert

Stato dell'autorizzazione:

Licence status A

Data dell'autorizzazione:

2014-04-02